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EPIGENETIC MECHANISMS IN HEALTH AND DISEASES
Lavinia Casati,1 aLessandra CoLCiago,2 and Fabio CeLotti 3
Epigenetic represents the programming of the genome to express the appropriate set of genes in specific cells 
at specific time points in life. The main epigenetic mechanisms are: 1 - methylation status of cytosines within CpG 
islands located in the promoter region of many genes; 2 - post-translational acetylation or methylation of lysines in 
the histone N-terminal region, which influence chromatin packaging; and 3 - production of non coding micro-RNAs 
involved in gene expression modulation. Epigenetic includes both heritable changes in gene activity and expression 
but also stable, long-term alterations in the transcriptional potential of a cell that are not necessarily heritable. These 
changes might be produced in particular by the early life environment (pollution, infection, maternal care, etc) and 
might affect health in adult life influencing the susceptibility to several diseases, such as cancer, psychiatric or neu-
rological disorders.
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MecanisMos epigenéticos na saúde e doença
Epigenética representa a programação do genoma para expressar o conjunto apropriado de genes em células 
específicas em momentos específicos da vida.
Os principais mecanismos epigenéticos são: 1 - metilação de citosinas nas ilhas CpG localizadas na região pro-
motora de vários genes; 2 - acetilação pós-translacional ou metilação de lisinas na região N-terminal da histona, que 
influencia a cobertura da cromatina; e, 3 - produção de micro-RNAs não codificantes envolvidos na modulação da 
expressão gênica. Epigenética inclui mudanças hereditárias na atividade e expressão do gene, mas também alte-
rações estáveis em longo prazo no potencial de transcrição de uma célula que não é necessariamente hereditária. 
Essas mudanças podem ser produzidas em especial pelo ambiente no início da vida (poluição, infecção, cuidados 
maternos, etc) e pode afetar a saúde na vida adulta, influenciando a susceptibilidade a diversas doenças, como 
câncer, psiquiátricas ou neurológicas. Ferramentas farmacológicas e outras formas de intervenção podem modificar 
potencialmente o padrão epigenético natural, oferecendo um caminho possível para reverter a programação epige-
nética deletéria
palavras-chave. Mecanismos epigenético; doença; meio-ambiente; comportamento; drogas.
RESUMO
ABSTRACT
Special article
inTRODUCTiOn
Epigenetics refers to heritable (meiotically or mitot-ically) patterns in phenotype or gene expression 
produced by mechanisms other than changes in the 
underlying DNA sequence; it represents the program-
ming of the genome to express the appropriate set of 
genes in specific cells at specific time points in life.
Epigenetic patterns are generated during cellular 
differentiation by a highly programmed and organized 
process, nevertheless, they are dynamic and respon-
sive to the environment especially during the criti-
cal periods of gestation and early life, but to a minor 
extent also later in life. Today the term epigenetics 
has widened to include both heritable changes in gene 
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Figure 1. DNA methylation at 5’cytosine and effects on gene transcription
activity and expression (in the progeny of cells or of 
individuals) but also stable, long-term alterations in 
the transcriptional potential of a cell that are not nec-
essarily heritable. These changes might be produced 
in particular by the early life environment and might 
affect the health in adult life influencing the suscepti-
bility to several diseases.
In eukaryotic cells epigenetic modifications are 
encoded via two primary modes: DNA methylation 
and histone modifications. Non coding microRNAs 
production and differences in chromatin-related pro-
teins are additional mechanisms involved in modulat-
ing gene expression.
BaSiC EPiGEnETiC MECHaniSMS
DNA methylation
It is the most frequently occurring epigenetic 
mechanism consisting in a covalent addition of a 
methyl group to the C5 position of cytosines that 
precede guanines in CpGs dinucleotides, called CpG 
islands1 (figure 1).
CpG islands are short stretches of DNA in which 
the frequency of the CG sequence is higher than in 
other regions. “p” simply indicates that cytosine and 
guanine are connected by a phosphodiester bond. 
CpG islands are often located around the promot-
ers of housekeeping genes or other genes frequently 
expressed in a cell (56% of genes).2 Unmethylated 
CpG islands are target of transcription factors to start 
the transcription. By contrast, the CpG sequences 
in inactive genes are usually methylated to suppress 
their expression. DNA methylation patterns correlate 
with chromatin structure: active regions, where genes 
are expressed, are associated with hypomethylated 
DNA sequences, whereas hypermethylated DNA is 
packaged in inactive chromatin.3
Two main mechanisms are involved in silencing 
gene expression by DNA methylation: direct interfer-
ence of methyl residues in binding of transcription 
factors4 and attraction of binding proteins, such as 
MeCP25 and/or histone modifying enzymes, which 
leads to a formation of “closed” chromatin configura-
tion associated with silencing of gene expression.5
Genomic DNA hypermethylation at one of the 
two parental alleles is also the basic mechanism of 
imprinting.6 Demethylation of imprinted genes rep-
resents an important mechanism of aberrant gene 
expression occurring in some diseases, as cancer. 
Methylation is also involved in X-chromosome inac-
tivation in females and in the induction of chromo-
somal stability through the hypermethylation of 
repetitive genomic sequences.7,8 
DNA methyltransferases (DNMTs) are the enzymes 
involved in methylation; at least three functional 
DNMTs have been identified in eukaryotic systems.
DNMT1 is involved in maintenance of methyla-
tion status during replication (it can methylate only 
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the CG sequence paired with methylated CG), while 
the other methylases contribute to the ‘de novo’ meth-
ylation pattern first established during embryonic 
development.9
Histone modifications
The basic repeating unit of chromatin, the nucleo-
some, consists of 146 bp of DNA wrapped around an 
octameric histone core formed by two copies each 
of histones H2A, H2B, H3, and H4. Histones beside 
possessing a definite structural function have a spe-
cific role in modulating the physical access of nuclear 
factors to DNA. It is now clear that post-translational 
modifications of charged aminoacids of histone tails 
that protrude from the core structure of the nucleo-
some can alter chromatin conformation and create 
binding sites for transcription factors playing a direct 
regulatory role in gene expression10 (figure 2). Six 
types of modification (methylation, acetylation, phos-
phorylation, ubiquitylation, sumoylation and proline 
isomerization) are possible on at least 30 sites for 
each nucleosome; it is therefore apparent that a very 
strong modulating activity can be produced by the 
Figure 2. Post-translational histone modifications
many possible combinations of modifications that can 
occur on a variety of sites on histones.11 
Some modifications, such as acetylation and 
phosphorylation, are reversible and dynamic and 
are thought to be involved in inducible expression 
of individual genes, while other modifications, 
such as methylation, are more stable and are pos-
sibly involved in the long-term maintenance of the 
expression status.11
Acetylation of histones decreases the affinity 
between the protein tail and DNA, thus relaxing the 
chromatin structure and allowing the recruitment of 
transcriptional machinery. Moreover it facilitates the 
binding of additional coactivators with domains that 
recognize acetylated lysines.
Generally, histone acetylation is associated 
with transcriptional activation,12 while the effect 
of histone methylation depends on the histone type 
and on the lysine position in the tail, even if meth-
ylation of histones is primarily found in transcrip-
tionally silenced heterochromatin regions.13
Among all the post-translational modifications of 
histones, methylation and acetylation of lysine resi-
dues in the amino-terminal tails of histones H3 and 
H414 are the best studied: methylation of histone H3 
at lysine 9 (H3K9) usually leads to transcriptional 
repression and can inhibit acetylation of the H3 tail at 
several lysines.
Histone methylation is catalyzed by histone lysine 
methyltransferases (HLMTase), while histone acetyl-
transferase (HAT) and histone deacetylases (HDACs) 
regulate, respectively, the acetylation and deacety-
lation of lysine residues.15 Recently described histone 
demethylases are involved in removing the meth-
ylation marks.16 It is noteworthy that CREB binding 
protein (CBP) is one known HAT and therefore chro-
matin structure might be regulated as part of CREB 
dependent activation of gene transcription in intracel-
lular signalling cascades involving cAMP, Ca2+ and 
extracellular signal regulated kinase (ERK).17 The 
DNA remodelling produced by intracellular signal-
ling is apparently very important in the neurobiologi-
cal adaptations associated with long-lasting behav-
iours in animal models and in the brains of humans 
with psychiatric conditions.17
Histone modifying enzymes are generally not gene-
specific. In response to putative environmental and 
other signals, specific transcription factors and tran-
scription repressors recruit histone-modifying enzymes 
to specific genes and define the gene-specific profile of 
histone modification.15 
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The processes of histone modification and DNA 
methylation are interdependent and both contribute 
to the overall state of chromatin and its epigenetic 
control of gene expression.18 For example the tran-
scriptional repressor, methyl-CpG binding protein 2 
(MeCP2), which binds to methylated CpG islands 
recruits histone deacetylases (HDAC) and core-
pressors, such as Sin3a.19 On the other hand his-
tone H3-K9 methylation creates a binding site for 
the Heterochromatin Protein (HP1) which recruits a 
DNA methyl transferase, capable to methylate DNA. 
In both cases, DNA methylation and histone modi-
fications act synergistically to repress transcription.
Histone modifications operate throughout differ-
entiation and development to specify gene expression 
but it is not yet clear if the modifications that have 
been generated, called histone marks, are heritable 
through generations in multicellular organisms.20
Small non coding RNAs
Another mechanism of gene regulation is medi-
ated by small, non coding RNAs. Among these small 
RNAs are the microRNAs (miRNAs) and short inter-
fering RNAs (siRNAs); they are both 20-30 nucleo-
tide-long double-stranded RNA molecules, encoded 
by their own set of genes (miRNAs) or introduced 
into the cell from outside sources (siRNAs).
The miRNAs are typically expressed in the 
nucleus in the form of longer precursors which are 
subsequently exported into the cytoplasm and pro-
cessed by the enzyme Dicer into ~22 nucleotide long 
miRNA. One single strand of these short RNAs, the 
mature guide or antisense strand, will next be loaded 
into the RNA-induced silencing complex RISC 
together with one or more Ago (Argonaute) protein, 
which will allow it to bind to its mRNA target and 
induce silencing (figure 3) (see 21, 22 for reviews). 
The siRNAs are more often produced by long, 
linear, perfectly base paired double strand RNA 
(dsRNAs) precursors introduced into the cell by virus, 
taken up from the environment or experimentally or 
clinically induced. More rarely precursors are endog-
enous products expressed by centromers, transposons 
or other repetitive sequences. These dsRNAs are then 
processed by Dicer enzymes and incorporated into 
RISC complexes in the same way as miRNAs. 
Dicer proteins cleave dsRNA precursors into 
20-30 nucleotide-long fragments through the action 
of two RNase III domains. The double-stranded prod-
ucts of Dicer enter into a RISC assembly pathway that 
involves separation of the two strands, followed by 
Figure 3. Mechanism of miRNA/siRNA maturation
the stable association of only one of the strands with 
an Ago effector protein. This guide strand recognizes 
each target messenger RNA by base pairing, whereas 
the other strand of the original small RNA duplex (the 
passenger strand) is discarded. Argonaute proteins are 
RNA silencing effectors endowed with an endonucle-
asic effect on the RNA target. The degradation effect 
of the Ago protein cleaves precisely the phosphodies-
ter linkage between the target nucleotides that are base 
paired to siRNA residues 10 and 11 (counting from 
the 5’ end). The generated fragments are then attacked 
by exonucleases to complete the degradative process. 
MicroRNAs play important roles in various biologic 
processes: they might regulate apoptosis, prolifera-
tion, differentiation, development, and metabolism 
affecting the expression of signalling molecules, such 
as cytokines, growth factors, transcription factors, 
proapoptotic and antiapoptotic genes etc. 
It is noteworthy that the availability of exoge-
nously delivered siRNAs or endogenously expressed 
microRNAs (by viral vectors) has generated a great 
optimism regarding potential RNA interference-based 
therapies for human disease (see below). 
EPiGEnETiCS anD HUMan DiSEaSES
The importance of epigenetics in human dis-
ease23-25 has been initially proposed in some rare inher-
ited diseases such as the Prader-Willi syndrome, the 
Angelmann syndrome and the Beckwith-Wideman 
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syndrome which are characterized by an epigenetic 
aberration of imprinted genes. More recently several 
genetic alterations of the enzymes involved in the 
epigenetic mechanisms have been discovered. For 
example, the Rett syndrome is a severe neurodevelop-
mental disease produced by mutations in the MeCP2 
gene which encodes the methyl CpG-binding protein 
2, a protein important in transcriptional repression 
(see above). The hypometilation of CpG sites is, on 
the other hand, the hallmark of the Immunodeficiency 
Centromeric Instability-Facial Anomalies Syndrome 
(ICF) characterized by immunodeficiency and facial 
anomalies. The syndrome is due to mutations in the 
coding region of the DNMT3b gene, which encodes 
a DNA methylase enzyme. Epidemiologically more 
relevant, even if still largely unexplored, is the associ-
ation of epigenetic aberrations produced by environ-
mental factors and the risk of developing frequently 
occurring diseases as cancer or immunological, car-
diovascular and psychiatric disorders.
Cancer
A vast and rapidly growing number of publica-
tions indicate that the epigenetic mechanisms have 
an important role in the development and progres-
sion of cancer (see 25, 26 for recent reviews). One 
of the first epigenetic alterations shown in human 
cancer is the hypomethylation of DNA occurring, in 
particular, in the repetitive DNA sequences and in 
the intronic sequences. During the development of a 
neoplasm, the degree of hypomethylation of genomic 
DNA increases as the lesion progresses from a benign 
proliferation of cells to a metastatic cell. Widespread 
hypomethylation has been associated with many can-
cers including: stomach, kidney, colon, pancreas, 
liver, uterus, lung and cervix.
Four mechanisms might explain the contribution 
of DNA hypomethylation to the development of a 
cancer cell: 
1. Generation of chromosomal instability: favours 
mitotic recombination leading to deletions, transloca-
tions, chromosomal rearrangements.
2. Reactivation of intragenomic transposable 
elements e.g. L1 (long interspersed nuclear ele-
ments) and Alu (recombinogenic sequence) repeats: 
these transposons can be transcribed or translocated 
to other genomic regions, thereby further disrupting 
the genome.
3. Loss of imprinting: for example loss of imprint-
ing of IGF2 gene produces an increased risk of 
colorectal cancer.
4. Frequently global hypomethylation correlates 
with hypomethylation of CpG islands in promoter 
regions of activating proto-oncogens increasing their 
expression and activating cell proliferation. 
Paradoxically, along with global hypomethyl-
ation, cancer cells also show localized regions of 
de novo hypermethylation, predominantly in CpG 
islands of tumor suppressor genes and microRNA 
(miRNA) genes. Inactivation of tumour suppres-
sor genes through hypermethylation of CpG islands 
within promoter regions is a major event in the origin 
of cancer.
Initially hypermethylation of the CpG islands 
was discovered in the promoter region of the retino-
blastoma tumor suppressor gene (Rb) but now the 
hypermethylation of the CpG island is considered a 
frequent mechanism of inactivation of genes involved 
in cell cycle control, DNA repair, metabolism of 
carcinogens, cell-to-cell interaction, apoptosis and 
angiogenesis, all of which are involved in the devel-
opment of cancer. 
Due to the above mentioned interaction between 
DNA methylation and histone modifications, it is not 
surprising that in many human cancers wide varia-
tions of the histone modification patterns occurs as a 
consequence of the wide changes of DNA methyla-
tion status.
For example hypermethylation of the CpG islands 
in the promoter regions of tumor-suppressor genes in 
cancer cells is associated with a particular combina-
tion of histone markers characterized by the hypo-
acetylated and hypermethylated histones H3 and H4. 
These changes are associated with silencing of certain 
tumor-suppressor genes; they appear early and accu-
mulate during the development of the tumor. Changes 
in histone modification patterns independent of the 
CpG methylation have also been directly linked to 
the development of cancer; they are due to the altered 
expression patterns of the histone-modifying enzymes 
which have been shown to occur in different cancer 
cells according to tumor type.
Recent studies have shown that profiles of miRNA 
expression differ between normal tissues and tumor 
tissues and among tumor types.
Down-regulation of subgroups of miRNAs, a 
common finding, might produce a loss of a tumor-
suppressor function for miRNAs, as shown for exam-
ple for RAS and BCL2 oncogenes.
DNA hypermethylation in the miRNA regulatory 
region is a mechanism that can account for the down-
regulation of miRNA in tumors.
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Aging
Although aging should not considered itself a 
human disease, the well-documented age-related 
phenotypes, such as functional decline and the devel-
opment of age-related diseases, might have a partial 
explanation in epigenetic changes accumulating dur-
ing life (see 20, 23, 27, 28 for reviews).
Two specific alterations of DNA methylation 
occur during aging: 
1. Global hypomethylation
2. Hypermethylation of specific loci (primarily 
CpG island promoters). 
The same modifications are known epigenetic 
alterations in cancer. This suggests that the accu-
mulation of epigenetic alterations during aging may 
directly contribute to malignant transformation.
Other epigenetic mechanisms, such as histone 
modifications, are also known to change during aging 
but have been less investigated.
Several histone-modifying enzymes are also 
known to have an important role in aging. Of these, 
the Sirtuin family of enzymes, which have histone 
deacetylase (HDAC) activity, deserves special atten-
tion. They are involved in the regulation of expression 
of genes controlling stress responses, DNA repair, 
apoptosis, cell cycle and insulin regulation. SIRT1 
is particularly relevant with respect to aging since it 
is expressed in most tissues and down-regulated in 
senescent cells and during aging. Recent evidence that 
small molecule activators of Sirtuins increase lifespan 
reinforces the importance of these HDACs in aging. 
The demonstration of age-accumulating epigene-
tic modifications supports the idea of age-related loss 
of normal epigenetic patterns as a possible mecha-
nism for the late onset of common human diseases.
One of the key issues in understanding the role of 
epigenetic modifications in the aging process is how 
epigenetic changes are generated. It is very likely that 
they may depend at least in part on environmental 
factors. If true, epigenetic represents a link between 
the environment, disease and aging. This assumption 
opens the possibility of targeted interventions aimed 
at improving life span or healthy aging.
EnViROnMEnTaL inFLUEnCES
Accumulating evidences indicate that the epig-
enome is an important target of environmental modi-
fications, which might produce effects on disease sus-
ceptibility and aging. Although epigenetic programs 
are established early in life, and therefore the devel-
opmental period represents the phase of maximal 
sensitivity to environmental influences, epigenetic 
alterations might occur during the whole life.
The early life and the postnatal environment have 
an important impact on health trajectories later in life 
and play a crucial role in generating vulnerabilities to 
chronic disease.16 It is established that adverse socio-
economic status during childhood anticipates vulner-
ability to developing chronic disease in adult life, 
related, for example, to blood pressure, cholesterol, 
fibrinogen and depressive symptoms.29 The memory 
of the intrauterine or early life exposure is maintained 
as stable change in gene expression programming: for 
example, maternal care in the rat can affect the long 
term programming of expression in the glucocorti-
coid receptor gene in the hippocampus.30 
Several environmental factors might be involved, 
alone or in combination, in producing changes in the 
epigenetic profiles of individuals. For example it has 
recently been shown that elderly monozigotic twin 
pairs, living separately in different locations, exhibited 
more epigenetic differences than young monozigotic 
twin pairs reared together. The demonstration of age-
accumulating epigenetic modifications supports the 
idea of age- and environment-related loss of normal 
epigenetic patterns as a possible mechanism for the 
late onset of common human diseases.
Pharmacological tools and other forms of inter-
vention may potentially modify the natural epigenetic 
pattern or reverse deleterious epigenetic program-
ming. Indeed, several epigenetic drugs are now at dif-
ferent stages of clinical trials for cancer and psychi-
atric disease.
Among the environmental agents affecting the 
epigenome profile, diet, infection, environmental 
toxins, endocrine disruptor compounds, wasting and 
smoking are the most studied.
S-adenosyl-methionine (SAM), introduced by 
diet, is the universal methyl donor for methyl transfer-
ases and is exclusively provided by folate-mediated 
one-carbon metabolism. Therefore a diet enriched or 
poor in folate can affect the activity of DNA methyl 
transferase and the methylation profile of DNA, 
consequently influencing gene expression.31 In rats, 
maternal protein restriction during pregnancy leads, 
in the offspring, to a loss of promoter methylation at 
gene associated with glucose metabolism, in tissues 
such as liver, lung and kidney.32 In humans, dietary 
restriction in methyl donors (no folate and choline, 
plus low methionine) as well as genetic polymor-
phisms in folate metabolism, have been associated 
with abnormal DNA methyl transferase expression, 
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global DNA hypomethylation, and increased cancer 
risk.31
Alcohol-induced alterations of the epigenome 
relates to its ability to increase methylation at gene 
promoters: this has been associated with methyla-
tion-induced silencing of tumor suppressor genes in 
colorectal cancer;33 also smoke has been demonstrated 
to increase methylation in tumor suppressor genes in 
human case-control studies and in mice and to reduce 
the methylation status of oncogenes in human cancer 
cell lines.34
The epigenetic profile of a host animal may be 
directly modified by bacterial infection, increasing 
or decreasing methylation, depending on the infec-
tious agent. Aberrant methylation of gastric mucosa 
genes is a common finding in humans infected with 
Helicobacter Pylori and is an early event in gastric 
carcinogenesis.35 Change in the epigenetic profile in 
response to infection may play a role in the develop-
ment of immune related disorders and cancers previ-
ously associated with infectious agents.31
Finally, the exposure to heavy metals, such as 
nickel, cadmium, and arsenic as well as to ionizing 
and ultraviolet radiations have all been associated 
with altered epigenetic profiles.36
The best studied epigenome modifiers are endo-
crine disruptors, a wide group of environmental com-
pounds with a large spectrum of disrupting actions 
on different endocrine systems; not only these com-
pounds are able to affect the epigenome in animals 
exposed in utero, but also their alterations can be 
transmitted from generation to generation when they 
occur in germ cells. 
Even if most genomic DNA methylation is erased 
between fertilization and pre-implantation,37 a lot of 
epigenetic modifications, acquired in pregnancy or 
in the foetal period in germ cells, can be transmitted 
down the generations.
An example of a transgenerational effect on epi-
genome by an endocrine disruptor compound is the 
effect of vinclozolin. Indeed, the antifungide vinclo-
zolin, which shows an antiandrogenic activity, affects 
DNA methylation patterns in the epydidimal sperm 
of treated animals (hypermethylation and hypometh-
ylation events) and the same modifications are evi-
dent also in sperm samples of vinclozolin-treated 
F2 and F3 generations. These modifications in the 
vinclozolin generations go in parallel with a signifi-
cant reduction of the testicular spermatid number, 
as well as the epididymal sperm number and motil-
ity, are significantly reduced in the vinclozolin 
generations compared to the control animals.38
In humans, prenatal exposure with diethystilbes-
trol, a synthetic estrogen, increases the risk of cervi-
cal and vaginal cancer in the female offspring (first 
generation, F1),39 whereas second generation (F2, 
daughters of the exposed offspring) shows menstrual 
irregularity and possible infertility; these data are 
compatible with speculation regarding transgenera-
tional transmission of DES-related epigenetic altera-
tions in humans.40 Indeed, in the reproductive tissues 
of DES exposed animals, an increase in promoter 
methylation of DNMTs inhibits their enzimatic activ-
ity, affecting the correct methylation pattern of repro-
ductive tissues.41 
Finally Bisphenol A is associated with higher 
body mass, impaired reproductive function and spe-
cific changes in DNA methylation in agouti mouse: 
these DNA alterations are present also in germ cells 
and are transmitted transgenerationally.42 Furthermore 
male rat offspring, perinatally exposed to Bisphenol 
A shows an impaired spermatogenesis starting from 
the first up to the third generation. This impairment 
seems to be related to a perturbation in protein expres-
sion profile of steroid receptor coregulators (such as 
steroid receptor coactivator-1, SRC-1, or 300/CBP/
cointegrator-associated protein, p/CIP) involved in 
regulation of the spermatogenesis.43
MaTERnaL BEHaViOUR
A new and very interesting field of epigenetic alter-
ations related to environmental stimuli is the effect on 
epigenome of different degrees of maternal care. 
For example, in rats, the adult offspring of moth-
ers that exhibit high levels of pup licking/grooming 
(LG) (i.e., High LG mothers) over the first week of 
life show increased hippocampal glucocorticoid 
receptor (GR) expression, related to an enhanced glu-
cocorticoid feedback sensitivity; indeed these animals 
show low DNA methylation in the regulatory regions 
of the glucocorticoid receptor (GR exon 17 promoter) 
gene in the hippocampus. Furthermore pups of high 
LG mothers show decreased hypothalamic corticotro-
phin releasing factor (CRF) expression, more modest 
HPA stress responses and increased behavioral explo-
ration related to decreased levels of stress-induced 
corticosterone.44
These differences in epigenetic programming 
emerge early in life in response to differences in 
maternal LG and remain stable into adulthood.
The mechanism by which maternal behavior trig-
gers the epigenetic modification seems to include a 
Lavinia Casati e CoLs.
216 Brasília Med 2010;47(2):209-218
signalling pathway that involves the serotonin recep-
tor, increase in cAMP, recruitment of the transcrip-
tion factor NGFI-A (a transcription factor induced by 
nerve growth factor), which in turn recruits a DNA 
demethylase MBD2 to the GR promoter.45
Differences in methylation degree of promoter 
region of estrogen receptor alpha are also related to 
low/high maternal care: the offspring of High LG 
mothers show a low degree of ER-alpha methylation, 
whereas low LG induces high methylation, inhibiting 
ER-alpha expression (figure 4).
The infusion to adult offspring of trichostatin-A 
(TSA), a demethylating agent, reverses the effects of 
low maternal LG; conversely, the central adminis-
tration of methionine, a methyl donor that promotes 
methylation, reverses the effect of high maternal 
LG.46 Moreover, epigenetic studies suggest that the 
accumulation of epigenetic variation in gene pro-
moters, through early-life environmental or stochas-
tic means, may account for changes in brain devel-
opment, behaviour, stress responsivity, and risk of 
mental illness. Recent studies in humans suggest that 
epigenetic processes, similar to those experimentally 
observed in rats, may play a significant role in shap-
ing human behavioral plasticity.
Figure 4. Differences in methylation degree of promoter  
region of ER-alpha related to maternal care
Brain-derived neurotrophic factor (BDNF) is a 
gene known to play an important role in cognition and 
aberrant regulation of this gene has been implicated in 
the etiology and pathogenesis of several cognitive and 
mental disorders, including schizophrenia: postmor-
tem reports have indicated that in the prefrontal cor-
tex and hippocampus of schizophrenic patients there 
is both decreased BDNF protein and BDNF mRNA 
levels.47
In rats, early negative social experiences trigger 
lasting changes in DNA methylation of BDNF CpG 
islands that are associated with decreases in BDNF 
expression in the adult prefrontal cortex.48
Even if there has been little investigation on BDNF 
DNA methylation in schizophrenia, the hypothesis of 
the hypermetylation triggered by an early adverse 
social environment and the consequent reduced gene 
expression is an attractive hypothesis.
To conclude, we can consider epigenetic as a 
mechanism that interfaces between nurture and 
nature, as Szyf suggests in his paper about “The early 
life environment and the epigenome”.
EPiGEnETiC DRUGS
As said before, pharmacological tools and other 
forms of intervention may potentially modify the 
natural epigenetic pattern offering a possible route to 
reverse deleterious epigenetic programming. 
Indeed, several epigenetic drugs are now at differ-
ent stages of clinical trials in cancer and psychiatric 
disease.
The first epi-drugs to be synthesized were the 
DNA Methyltransferase (DNMT) Inhibitors nucleo-
side analogues 5-azacytidine (azacitidine; Vidaza) and 
5-aza-2′-deoxycytidine (decitabine; Dacogen), ini-
tially developed as cytotoxic agents to treat leukemia.
Azacitidine and decitabine have cytotoxic effects, 
but at lower doses these agents are predominantly 
epigenetic modulating. The nucleoside analogues are 
S-phase specific and mainly exert their effects after 
incorporation into the DNA: the DNA/nucleoside-
analog complex stoichiometrically binds to DNMTs. 
This results in a cellular depletion of DNMTs and sub-
sequent hypomethylation of newly synthesized DNA 
strands.49, 50 FDA approved Azacitidine and decitabine 
for the treatment of myelodysplastic syndrome in 
2004 and 2006, respectively. Other inhibitors of 
DNMTs are non nucleoside analogs, as procaine, pro-
cainamide and hydralazine; they act as low inhibitors 
of DNMTs, without requiring DNA incorporation. 
These compounds are still experimental drugs.51
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Histone deacetylase inhibitors (HDAC inhibitors) 
are to the second class of epigenetic drugs. They are 
structurally heterogeneous but share a common abil-
ity recognize and bind to the catalytic zinc-pocket on 
class I and II HDAC (valproic acid or hydroxamic 
acid). HDAC inhibitors can induce in vitro cell cycle 
arrest and differentiation. These drugs are currently 
under clinical phase II or I trials.51
SiRNA can be engineered to specifically silence 
any gene with a known sequence; their delivery, 
either directly or by means of viral vectors, represents 
a potential new therapeutic tool.
A series of successful pre-clinical studies in small 
animals and initial clinical studies in humans have 
been done (Phase I, Phase II and III trials);52 although 
some disadvantages, as specificity of siRNA, delivery 
of siRNA to target tissue, immunogenicity and liver 
damage, still remain, it is possible that future devel-
opments might provide valuable drugs to suppress 
unwanted gene expression.
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